%0 Journal Article
%T Real-life Results of a Cohort of Retroperitoneal Sarcomas (RPS): Management at Hassan II University Hospital in Fes
%A Medyouni Hajar
%A Chouef Jihane
%A Siyouri Oumaima
%A Chbihi Chaymae
%A Saoudi Amira
%A Amaadour Lamiae
%A Oualla Karima
%A Benbrahim Zineb
%A Arifi Samia
%A Mellas Nawfel
%J Open Access Library Journal
%V 11
%N 4
%P 1-8
%@ 2333-9721
%D 2024
%I Open Access Library
%R 10.4236/oalib.1111439
%X Retroperitoneal sarcomas (RPS) pose a challenge in treatment due to their rarity and complex nature. This retrospective study aimed to analyze the epidemiological, clinicopathological characteristics, and survival outcomes of RPS patients treated over an 11-year period. Seventeen patients diagnosed with RPS were included, with leiomyosarcoma being the most prevalent subtype. Surgical excision was the primary treatment modality, often complemented by radiotherapy and chemotherapy. The 5-year and 10-year overall survival rates were 56% and 46.9%, respectively, with a median progression-free survival of 10 months.
Discussion highlights the importance of complete surgical resection and tumor grade as prognostic indicators. Local recurrence remains a significant concern despite advancements in treatment modalities. The role of radiotherapy in reducing local recurrence risk is acknowledged, particularly in the preoperative setting. For metastatic RPS, a multidisciplinary approach integrating surgery and systemic therapy is crucial. Patient selection for surgical interventions considers tumor biology, disease burden, and response to chemotherapy. Chemotherapy, primarily anthracycline-based, remains a cornerstone in managing unresectable or metastatic disease, with emerging agents showing promise in clinical trials. Overall, a tailored treatment approach emphasizing radical resection and adjuvant therapies offers the best chance for long-term survival in RPS patients.
%K Retroperitoneal sarcomas (RPS)
%K Multidisciplinary approach
%K Chemotherapy
%K Metastatic disease
%U http://www.oalib.com/paper/6820503